50.08
0.00
(0.00%)
May 24 - Close
EPA
data delayed by 15 mins -
Disclaimer
Currency in EUR
| Range | 50.00 - 50.40 |
| 52 week | 40.50 - 55.00 |
| Open | 50.25 |
| Vol / Avg. | 2,506.00/5,784.00 |
| Mkt cap | 676.05M |
| P/E | 18.13 |
| Div/yield | 0.75/1.50 |
| EPS | 2.76 |
| Shares | 13.50M |
| Beta | - |
| Inst. own | - |
Events
Jul 25, 2013
Half Year 2013 Stallergenes SA Earnings Release
- 6:00PM GMT+2 -
Apr 22, 2013
Q1 2013 Stallergenes SA Sales Conference Call
Apr 22, 2013
Q1 2013 Stallergenes SA Sales Release
Mar 8, 2013
Full Year 2012 Stallergenes SA Earnings Presentation -
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | 10.60% | 15.59% |
| Operating margin | 16.15% | 23.17% |
| EBITD margin | - | 28.98% |
| Return on average assets | 8.62% | 13.91% |
| Return on average equity | 12.92% | 21.47% |
| Employees | 1,001 | - |
| Carbon Disclosure Rating | - | - |
Address
6 rue Alexis de Tocqueville, ANTONY Cedex
ANTONY, 92183
France
+33-1-55592310 (Phone)
+33-1-55592068 (Fax)
ANTONY, 92183
France
+33-1-55592310 (Phone)
+33-1-55592068 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Stallergenes SA is a France-based biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis, rhinitis and allergic asthma. It has developed a range of in vivo and in vitro tests for use in the medical profession. The Company's range of products includes more than 150 references. The Company also has research and development teams divided between clinical development, laboratory research and development of candidate products, and regulatory affairs. Stallergenes SA is present in almost 40 countries via ten subsidiaries in Europe in Germany, Italy, Spain, Belgium, Switzerland, the Netherlands, the Czech Republic, Slovakia, Austria and Great Britain, and has entered into numerous partnerships and distribution agreements. As of December 31, 2011, Stallergenes SA was 73.4%-owned by Ares Life Sciences.
Officers and directors
| Roberto Gradnik MD | Chief Executive Officer, Member of the Management Committee and Executive Committee | |
| Laurent Artaud | Member of the Management Committee, Deputy CEO, Chief Pharmacist, Quality Director | |
| Christian Thiry | Member of the Ex.Com., Member of the Mgt.Com, Director of Finance and Administration | |
| Victor Alva Celma | Head of Spain-based subsidiary | |
| Urs Amstutz | Head of Switzerland-based subsidiary | |
| Maurizio Capecce | Head of Italy-based Subsidiary | |
| Nienke Guhl | Head of Germany-based Subsidiary | |
| Mark Hut | Head of Netherlands-based subsidiary | |
| Sebastien Iva | Director of Development of Central Europe and Orient | |
| Ingrid Lansard | Head of the Belgium-based subsidiary |